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Abstract
The present study is the ﬁrst to examine the modulation of retinal kynurenic acid (KYNA) content in response to N-methyl-D-
aspartate (NMDA)-induced cell death in adult rat retinal ganglion cells (RGC). Adult Brown Norway rats were intravitreally in-
jected with NMDA or PBS. Surviving RGC were retrogradely labeled with ﬂuorogold and counted in wholemounts of retinas 2, 7
and 14 days after injection. Retinal KYNA content was measured by HPLC at the same time points. RGC numbers decreased
signiﬁcantly 2, 7 and 14 days after NMDA injection if compared to control retinas. KYNA concentration increased signiﬁcantly two
days after NMDA-injection. However, 7 and 14 days after injection retinal KYNA content was found markedly decreased in
NMDA-treated eyes as compared to controls. It is conceivable that KYNA deﬁciency is causally related to the pathology of ex-
citotoxic retinal diseases.
 2003 Elsevier Science Ltd. All rights reserved.
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1. Introduction
The tryptophan metabolite kynurenic acid (KYNA)
is the only known endogenous antagonist of ionotropic
glutamate receptors and it acts as a neuroprotectant
(Foster, Vezzani, French, & Schwarcz, 1984; Taber,
Baker, & Fibiger, 1996).
In mammalian brain, KYNA is formed by irreversible
transamination of L-kynurenine (L-KYN) by kynure-
nine aminotransferases (KAT I and KAT II) (Guidetti,
Okuno, & Schwarcz, 1997). KAT I, a soluble enzyme
which prefers pyruvate as a co-substrate (Okuno et al.,
1990), has been localized immunohistochemically in
the rat brain, medulla and spinal cord (Du et al., 1992;
Kapoor, Okuno, Kido, & Kapoor, 1997; Knyihar-
Csillik, Okuno, & Vecsei, 1999; Roberts, Du, McCarthy,
Okuno, & Schwarcz, 1992). KAT II was ﬁrst identiﬁed
by Northern Blot mRNA analysis in the human brain
(Okuno, Nakamura, & Schwarcz, 1991). KAT II, which
in contrast to KAT I has a pH optimum in the physio-
logical range (Okuno et al., 1991), appears to be re-
sponsible for most KYNA formation under physiologic
conditions (Guidetti et al., 1997).
KYNA has been identiﬁed and quantiﬁed in the ret-
ina of adult rats (Rejdak et al., 2001). Retinal KYNA
concentrations were in the same range as in the rabbit
vitreous body (Zarnowski et al., 2001) and similar to
those observed in the rat, rabbit and human brain
(Moroni, Russi, Lombardi, Beni, & Carla, 1988; Turski
et al., 1988). Immunohistochemical experiments using
KAT I and KAT II antibodies (Okuno et al., 1991;
Okuno, Tsujimoto, Nakamura, & Kido, 1993) showed
that both enzymes are present in the rat inner retina.
KAT I is preferentially expressed in M€uller cell endfeet,
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while KAT II is localised in cells within the ganglion cell
layer (Rejdak et al., 2001). Only recently, the presence of
KYNA and developmental changes of its content in
both vascularised rat and avascular chicken retinas
during ontogeny have been reported (Rejdak et al.,
2002).
The mammalian retina is highly susceptible to N -
methyl-D-aspartate (NMDA) toxicity (Sabel, Sautter,
Stoehr, & Siliprandi, 1995; Siliprandi et al., 1992), and
NMDA-induced neuronal degeneration was found to be
mainly restricted to the innermost retinal layers (Silip-
randi et al., 1992). This pattern closely resembles retinal
ganglion cells (RGC) loss in several ophthalmic diseases,
including retinal ischemia, glaucoma and optic neurop-
athy (Dreyer, Pan, Storm, & Lipton, 1994; Sucher,
Lipton, & Dreyer, 1997). If NMDA triggers calcium
channels to induce apoptosis in neural tissue (Lam,
Abler, Kwong, & Tso, 1999; Yu, Yeh, Strasser, Tian, &
Choi, 1999) how does a spike in NMDA levels alter
KYNA content? To answer this question the present
study examined the eﬀect of NMDA-induced RGC
death on retinal KYNA content.
2. Material and methods
All experiments were performed in compliance with
the guidelines of animal care in the European Commu-
nity and the Association for Research in Vision and
Ophthalmology.
2.1. Intravitreal injections of NMDA and PBS
Adult male Brown Norway rats were anaesthetized
with an intraperitoneal injection of chloral hydrate (6
ml/kg body weight of a 7% solution). NMDA was dis-
solved in 0.2 M sterile phosphate-buﬀered saline (PBS,
pH 7.4) at a ﬁnal concentration of 10 mM for intravi-
treal injection. Eyes were injected intravitreally using a
heat-pulled glass-capillary connected to a microsyringe
(Drummond Scientiﬁc Co., Broomall, PA) under direct
observation through the microscope. Animals with vis-
ible lens damage were excluded from the experiments
and not analyzed thereafter.
A single injection of 2 ll of 10 mM NMDA (or 20
nmol) was given. Contralateral eyes served as control
eyes and were injected with PBS.
2.2. Quantiﬁcation of retinal ganglion cells
Labeling was performed either on the day of NMDA
injection (for two-day survival) or ﬁve days after
NMDA injection. Animals were anaesthetized deeply
and a total of 7 ll of the ﬂuorescent tracer hydroxy-
stilbamidine methanesulfonate (Fluorogold, Molecular
Probes, Eugene, OR) was applied into each of the su-
perior colliculi by three stereotaxic injections. Two days
later animals were killed by chloral hydrate overdose,
the eyes were enucleated, retinas dissected, ﬂat-mounted
on cellulose nitrate ﬁlters (pore size 60 lm; Sartorius,
Long Island, NY), and ﬁxed in 2% PFA for 30 min.
Labeled cells were deﬁned as surviving. Observation was
performed under a ﬂuorescence microscope immedi-
ately, and counting was carried out in 12 distinct areas
of 62,500 lm2 per retina. Three areas per retinal quad-
rant at three diﬀerent eccentricities of one-sixth, one-
half, and ﬁve-sixths of the retinal radius were counted
(Kl€ocker, Cellerino, & B€ahr, 1998).
Images were obtained via a digital imaging system
connected to the microscope (ImagePro), coded and
analyzed semi-automatically in a masked fashion using
a computer-assisted image analysis system.
2.3. Analysis of KYNA
Retinal KYNA content was measured 2, 7 and 14
days after NMDA injections. The animals were killed
with CO2, and the eyes were removed. To obtain iso-
lated neural retinas, the eyes were opened along the ora
serrata and cornea, and the lens and vitreous body were
removed. Using a pair of forceps, the whole neural
retinas were then carefully dissected free from the retinal
pigment epithelium and sclera. Retinas were immedi-
ately frozen in liquid nitrogen after removal.
2.4. HPLC
KYNA levels were investigated according to the
method of Turski and colleagues (Turski et al., 1988).
Specimens were sonicated in 2 vols (w/v) of distilled
water, immersed in a boiling water bath for 10 min and
centrifuged (10 min, 20,000 rpm). The resulting super-
natant was diluted (1:1) with 0.2 N HCl and applied to a
Dowex 50-W hydrogen form pre-washed with 0.1 N
HCl. Columns were subsequently washed with 1 ml 0.1
N HCl and 1 ml water. KYNA was eluted with 2 ml of
water. The elute was subjected to HPLC and KYNA
was detected ﬂuorimetrically according to the method of
Shibata (Shibata, 1988). HPLC reagents used in the
study were obtained from Baker (Griesheim, Germany)
and were of the highest available purity. Statistical
analysis was performed using paired Students t test.
3. Results
After injury (Mittag et al., 2000; Vorwerk et al.,
1996b), RGC were labeled by stereotaxic injections into
each superior colliculus. RGC numbers decreased sig-
niﬁcantly (p < 0:001) 2, 7 and 14 days after NMDA
injection compared to control retinas. After two days,
treatment with NMDA resulted in an RGC count of
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1277 68 (mean  standard deviation) per mm2
(n ¼ 4), (PBS injected eyes showed ganglion cell counts
of 2378 81; n ¼ 4). 557 250 RGC/mm2 survived se-
ven days after NMDA injection (n ¼ 6), (PBS injected
eyes had 2329 351 RGC/mm2, n ¼ 7). 14 days after
NMDA injection, 224 94 cells/mm2 were counted
(n ¼ 5), compared to 2108 189 RGC/mm2 after PBS,
n ¼ 5 (Figs. 1 and 2). PBS injections did not have any
inﬂuence on RGC survival if compared to untreated
eyes (data not shown). The concentrations of KYNA
measured in retinas of PBS injected eyes were in close
agreement with those observed in the previous study
(Rejdak et al., 2001).
NMDA-treated eyes displayed a signiﬁcantly higher
(p ¼ 0:03) retinal KYNA concentration (136 11 pmol/
g wet wt, mean  standard error, n ¼ 10) two days after
injection compared to PBS-injected group (109 6
pmol/g wet wt, n ¼ 10). However, seven days after in-
jection retinal KYNA content markedly decreased
(p ¼ 0:02) to 83 5 pmol/g wet wt. (n ¼ 9) in NMDA-
treated eyes compared to control values (118 10 pmol/
g wet wt, n ¼ 10). A similar eﬀect of NMDA-induced
damage on retinal KYNA content was also observed 14
days after NMDA injection as compared to PBS-
injected group (127:8 9 pmol/g wet wt, n ¼ 7) (91:6
8 pmol/g wet wt, n ¼ 7) (Fig. 3).
4. Discussion
The present study was designed to investigate the
modulation of retinal KYNA content in response to
NMDA toxicity to RGC at various time points fol-
lowing intravitreal NMDA injection. The loss of RGC
is a hallmark of many ophthalmic diseases including
glaucoma, retinal ischemia and optic neuropathy (Dre-
yer et al., 1994). Recent studies have indicated that
glutamate aﬀects RGC predominantly through the
NMDA receptors (Sucher et al., 1997). It has been also
suggested that AMPA and kainate receptor subtypes
may also contribute to RGC loss (Otori, Wie, & Barn-
stable, 1998; Schuettauf, Naskar, Vorwerk, Zurakowski,
& Dreyer, 2000). Since dysfunction of KYNA synthesis
in the brain may be an important factor contributing to
neuronal degeneration (Foster et al., 1984; Schwarcz
et al., 1992), KYNA may have also relevance to the
mechanisms of RGC loss.
Our study showed that RGC numbers decreased
signiﬁcantly two days after intraocular NMDA injec-
tions. During the same time, retinal KYNA contents
increased markedly to 124% of control values. Increases
in KYNA formation during the initial phases of ex-
citotoxic injury may provide enhanced neuroprotection;
it has been suggested that this is a factor in endogenous
Fig. 1. Whole mounts of rat retina after NMDA injection; ganglion cells have been back-labeled by injection of ﬂuorogold. (A) Control, (B) two
days after injection, (C) seven days after injection, (D) 14 days after injection.
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anti-excitotoxic defence mechanisms in the CNS (Ure-
njak & Obrenovitch, 2000). Such a lesion-induced rise in
retinal KYNA levels may be explained either by an
enhanced inﬂux of blood-borne L-KYN due to a com-
promised blood-retina barrier (Hamilton & Gould,
1987) or by increased cerebral biosynthesis of L-KYN at
the lesion site (Saito, Lackner, Markey, & Heyes, 1991).
Other factors, like compounds released from damaged
and dying neurons, activated microglia, and/or inﬁl-
trating macrophages may contribute as well (Marty,
Dusart, & Peschanski, 1991). These compounds are
known to play an active role during the initial days
following excitotoxic insult (Lees, 1993). Interestingly,
Ceresoli-Borroni et al., reported a dramatic increase of
striatal KYNA content two days after quinolinate in-
trastriatal injections (Ceresoli-Borroni, Guidetti, &
Schwarcz, 1999). Additionally, a similar eﬀect was ob-
served after an intrastriatal ibotenate injection (Ceresoli,
Guidetti, & Schwarcz, 1997).
In our study, the retinas of NMDA-treated eyes dis-
played a marked decrease in RGC numbers 7 and 14
days after injection compared both to controls and to
numbers observed two days after NMDA injection.
Correspondingly, KYNA concentrations decreased to
70% of control values at days 7 and 14. It appears that
the loss of RGC in that period of time might account for
a decrease in retinal KYNA content, since immunohis-
tochemical studies showed preferential localisation of
KAT II on RGC (Rejdak et al., 2001). In contrast to the
retina, KYNA content increased in the brain seven days
after intrastriatal or intrahippocampal application of
NMDA–agonist–quinolinate (Ceresoli-Borroni et al.,
1999; Wu, Baran, Ungerstedt, & Schwarcz, 1992). This
increase has been attributed to massive gliosis following
neuronal cell death induced by neurotoxin (Ceresoli-
Borroni et al., 1999; Wu et al., 1992). In the brain, KAT
was found mainly in glia cells and it appears that they are
responsible for most KYNA formation (Roberts et al.,
1992; Tamburin, Mostardini, & Benatti, 1999). In the
retina, neuronal damage due to neurotoxin administra-
tion induces reactive proliferation of M€uller cells (Dyer
& Cepko, 2000). It can be speculated, however, that these
cells produce only limited amount of KYNA since they
contain almost exclusively KAT I (Rejdak et al., 2001),
which has an optimum at non-physiological pH of 9.5.
This may explain the decrease found in our study in
KYNA concentrations in retinas lesioned with NMDA.
KYNA deﬁciency has been suggested to be causally
related to the pathology of excitotoxic brain diseases
(Schwarcz et al., 1992). Decreased KYNA production
was demonstrated in the brain of patients with Hun-
tingtons disease (Beal, Matson, Swartz, Gamache, &
Bird, 1990; Jauch et al., 1995). Additionally, in vivo
studies have shown that reduction of KYNA synthesis
in the rat brain using non-speciﬁc inhibitors can lead to
neurotoxicity (Beal, Ferrante, Swartz, & Kowall, 1991;
Urbanska, Ikonomidou, Sieklucka, & Turski, 1991).
Preferential loss of layer III of the entorhial cortex after
local injection of a non-speciﬁc inhibitor of KYNA
synthesis was suggested as a signiﬁcant factor in the
pathophysiology of temporal lobe epilepsy (Du, Eid, &
Schwarcz, 1998), and is likely to be involved in the
pathophysiology of several neuropsychiatric diseases,
such as Alzheimers disease and schizophrenia (Arnold,
Hyman, Van Hoesen, & Damasio, 1991; Hyman, Kro-
mer, & Van Hoesen, 1987). The decrease of KYNA after
day 2 may have led to the dramatic loss of RGC seen at
this timepoint in our experiments.
Otherwise, the endogenous glutamate antagonist
KYNA was shown to prevent excitotoxic neuronal
damage (Andine et al., 1988; Foster et al., 1984). It was
found that an increase in brain KYNA concentration
2 days after injection 7 days after injection 14 days after injection
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Fig. 2. RGC survival at 2, 7 and 14 days after NMDA or PBS in-
jections. Values represent the mean  standard deviation. (  ) in-
dicates signiﬁcantly higher RGC survival at all given time points
compared to controls (p < 0:001 for each) by paired t-test. (###) in-
dicates a signiﬁcant loss of RGC between days 2 and 7 and days 7 and
14 after NMDA injection (p < 0:001 for each).
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Fig. 3. Eﬀect of NMDA-induced RGC damage on retinal KYNA
content. Each column represents the mean KYNA concentration
(pmol/g wt wet SE). White column––PBS-injected eyes, black col-
umn––NMDA-injected eyes. (A) Normal KYNA concentration in the
retina (Rejdak et al., 2001), (B) two days after injection, (C) seven days
after injection, (D) 14 days after injection. () indicates signiﬁcantly
diﬀerent KYNA content at all given time points if compared to con-
trols (p < 0:05 for each) by paired t-test.
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either directly, or through enhanced KYNA synthesis
may be neuroprotective. In experimental brain ischemia
neuroprotection was observed following systemic ad-
ministration of KYNA (Andine et al., 1988; Salvati
et al., 1999), L-KYN (Nozaki & Beal, 1992) as well as
kynurenine-3-hydroxylase inhibitors (Cozzi, Carpenedo,
& Moroni, 1999; Moroni, Cozzi, Peruginelli, Carpen-
edo, & Pellegrini-Giampietro, 1999). Importantly, sys-
temic L-KYN administration partially protects against
NMDA-induced degeneration of RGC, and reduces
visual discrimination deﬁcits in adult rats (Vorwerk,
Kreutz, Dreyer, & Sabel, 1996a).
Neuroprotective properties of KYNA are usually
explained by its ability to block the excitatory amino
acid receptor functions, but this is still debated. Under
physiological conditions, KYNA concentrations (150
pmol/g in the human neocortex or at less than 50 pmol/g
in the whole rat brain) are far lower than those required
to antagonize EAA receptor functions established in in
vitro electrophysiological studies (IC50 ¼ 8–15 lM) (see
Erhardt, Oberg, Mathe, & Engberg, 2001 and references
cited there). Indeed, systemic administration of KYNA
which produced neuroprotective eﬀects in gerbils, was
associated with a more than 250-fold transient rise of
brain KYNA (Salvati et al., 1999). Regardless of its
action on EAA receptors, KYNA is also a potent
non-competitive antagonist of acetylcholine a7 nicotinic
receptors, and it may also inhibit glutamate release
indirectly via this mechanism (Carpenedo et al., 2001;
Hilmas et al., 2001). A fourfold elevation of brain
KYNA (to approx 125 pmol/g) by i.v. treatment of rats
with PNU 156561A, a potent inhibitor of kynurenine 3-
hydroxylase, was suﬃcient to abolish the glutamatergic
component of activation of nigral dopaminergic neurons
by nicotine (Erhardt et al., 2001). Thus, even a moderate
increase in brain KYNA level may produce signiﬁcant
eﬀects on the tonic glutamatergic control. In the retina,
were able to show a moderate increase of KYNA two
days after NMDA-induced RGC damage.
KYNA is formed by irreversible transamination of L-
kynurenine (L-KYN) which is also a precursor of quin-
olinic acid (QUIN), 3OH-kynurenine (3OH-KYN) and
3OH-anthranilic acid. QUIN is an agonist of the sub-
population of NMDA receptors and neurotoxin. 3OH-
kynurenine (3OH-KYN) and 3OH-anthranilic acid may
cause both apoptotic and necrotic neuronal death
(Moroni et al., 1999; Stone, 2001; Eastman & Guilarte,
1989). It has been found that pharmacological depletion
of QUIN and 3OH-KYN synthesis exerts a protective
eﬀect in experimental brain ischemia (Moroni et al.,
1999). Similar protective eﬀects were observed after the
enhancement of endogenous KYNA levels in the brain
(Nozaki & Beal, 1992), indicating that an imbalance in
kynurenine metabolism may have profound implications
for neuronal function and cell loss, especially if that
imbalance is present chronically (Stone, 1993).
In conclusion, retinal KYNA concentrations change
in response to NMDA-induced RGC damage. The data
demonstrate that there is a neuroprotective response to
either toxic NMDA insult or RGC death. That response
is an increase of KYNA. It is therefore conceivable that
relative KYNA deﬁciency is an important factor con-
tributing to the mechanisms of neuronal degeneration in
the retina. Studies on KYNA synthesis in the retina in
other model systems of retinal degeneration are recom-
mended.
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